A new nutraceutical (Livogen Plus®) improves liver steatosis in adults with non-alcoholic fatty liver disease

Abstract

Background Currently, there is no approved medication for non-alcoholic fatty liver disease management. Pre-clinical and clinical studies showed that several bioactive molecules in plants or foods (i.e., curcumin complex, bergamot polyphenol fraction, artichoke leaf extract, black seed oil, concentrate fish oil, picroliv root, glutathione, S-adenosyl-l-methionine and other natural ingredients) have been associated with improved fatty liver disease. Starting from these evidences, our purpose was to evaluate the effects of a novel combination of abovementioned nutraceuticals as a treatment for adults with fatty liver disease. Methods A total of 140 participants with liver steatosis were enrolled in a randomized, double-blind, placebo controlled clinical trial. The intervention group received six softgel capsules daily of a nutraceutical (namely Livogen Plus®) containing a combination of natural bioactive components for 12 weeks. The control group received six softgel capsules daily of a placebo containing maltodextrin for 12 weeks. The primary outcome measure was the change in liver fat content (CAP score). CAP score, by transient elastography, serum glucose, lipids, transaminases, and cytokines were measured at baseline and after intervention. Results After adjustment for confounding variables (i.e., CAP score and triglyceride at baseline, and changes of serum γGT, and vegetable and animal proteins, cholesterol intake at the follow-up), we found a greater CAP score reduction in the nutraceutical group rather than placebo (− 34 ± 5 dB/m vs. − 20 ± 5 dB/m, respectively; p = 0.045). The CAP score reduction (%) was even greater in those with aged 60 or less, low baseline HDL-C, AST reduction as well as in men. Conclusion Our results showed that a new combination of bioactive molecules as nutraceutical was safe and effective in reducing liver fat content over 12 weeks in individuals with hepatic steatosis. Trial registration ISRCTN, ISRCTN70887063. Registered 03 August 2021—retrospectively registered, https://doi.org/10.1186/ISRCTN70887063

What’s New in the Treatment of Non-Alcoholic Fatty Liver Disease (NAFLD)

“…A 12-week follow up to supplementation with Livogen Plus ® at a dose of six capsules per day resulted in reductions in liver steatosis in 62% of patients. Moreover, improvements in insulin resistance and decreases in diastolic blood pressure and oxidative stress, demonstrated by an increase in biological antioxidant potential, were observed [76]. Efficiency in hepatic fat reduction was also proven for another nutraceutical administered through 12-week supplementation, containing extracts from Bergamot polyphenolic fraction and Cynara Cardunculus, at a dose of 300 mg per day [77].…”

Exploring the Impact of Nutrition on Non-Alcoholic Fatty Liver Disease Management: Unveiling the Roles of Various Foods, Food Components, and Compounds

“…A lot of studies confirmed the usefulness of using functional foods in the context of NAFLD treatment. Among beneficial outcomes, improvements in anthropometric measures, liver function, hepatic fat amounts, and glucose maintenance parameters can be specified [ 206 , 207 , 208 ]. To provide better clarity, we will present the composition of the given nutraceuticals and their impact on the condition of patients with NAFLD in the form of a table.…”

Особливості Впливу Комплексу Ліводінол® У Пацієнтів З Неалкогольною Жировою Хворобою Печінки (Власне Дослідження)

“…Комплекс Ліводінол® містить 3 амінокислоти (адеметіонін, L-глутатіон та N-ацетилцистеїн), що чинять позитивні метаболічні та антиоксидантні ефекти [9][10][11][12][13].…”